With anti-blue glasses, go to the big pharmacy to brush the medical insurance card. The big pharmacy and Yunnan Baiyao Taibang start strategic cooperation.
Release time:
2021-04-21
News from our newspaper # February 16 , Yunnan Baiyao Taibang and Jianfeng Pharmacy Chain Eye Health Strategy Launch Meeting was held in Jianfeng Building. As the first glasses product in the country to be registered and listed with national II medical devices, Yunnan Baiyao Taibang Medical Optical Radiation Protective Glasses are preferred to be settled in Jianfeng Pharmacy in Zhejiang.
In modern life, the harm of blue light emitted by electronic products is everywhere. Anti-blue glasses have a certain technical threshold , lead to many so-called "anti-blue lenses" on the market quality is uneven, careless choice will damage the eye health. Yunnan Baiyao Taibang medical optical radiation protection glasses overcome the disadvantages of traditional film reflection technology, such as reducing lens light transmittance, affecting lens clarity, film damage and loss of protective performance, etc., and adopt substrate absorption technology to effectively block high-energy and harmful blue light released by electronic products. At the beginning of the product's launch in the second half of 2020, Spike Pharmacy introduced pilot sales and achieved good sales without large-scale publicity. On this basis, Jianfeng Pharmacy and Yunnan Baiyao Taibang further carried out in-depth cooperation, becoming the first pharmaceutical retail enterprise in Zhejiang Province to enter the II medical device fitting glasses project. Strengthening the in-depth cooperation with superior brand enterprises has always been an important direction for the peak pharmacy to seek breakthroughs. Yunnan Baiyao is a well-known national medicine time-honored brand with a complete range of products and great brand influence. It has maintained a good cooperative relationship with Jianfeng Pharmacy for many years. Although anti-radiation glasses are a new industrial field of Yunnan Baiyao Group, with the wide application of electronic products, the relevant market potential is huge, which also brings good prospects for the cooperation between the two sides.
It is understood that Jianfeng Pharmacy will take the lead in opening a special counter for fitting mirrors in Jiangjun Road Store and Yishou Shenhang Store in Jiangbei, Jinhua City, to provide experiential and professional services to customers. Customers optometry can be paid by brushing the medical insurance card, which is very convenient. After that, the two sides will rely on stores to carry out the market layout of eye health one-stop service around the glasses business. (Reporter
Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page